Typical influenza vaccines, including the well-established egg-based inactivated and live-attenuated formulations, have served the global population for decades but come with inherent limitations. Production timelines are lengthy, often six months or longer, constraining rapid responses to emergent viral strains. Moreover, these vaccines frequently suffer from suboptimal immunogenicity, particularly in immunocompromised individuals or the elderly, and their efficacy can be eroded by antigenic drift leading to strain mismatch. Therefore, the scientific community is urgently seeking innovative platforms that offer rapid programmability and robust, broad-spectrum immunogenicity with enhanced biosafety profiles.

At the forefront of this endeavor is an ingenious strategy involving the incorporation of non-canonical amino acids (ncAAs) into influenza viral proteins, enabling precise attenuation of viral replication without compromising antigen presentation or immunogenic potential. This approach leverages the introduction of premature termination codons (PTCs) into essential viral genes, creating “PTC viruses” whose replication is tightly controlled by an orthogonal translation system. This system comprises a unique tRNA/aminoacyl-tRNA synthetase pair that exclusively recognizes the designated ncAA, ensuring site-specific suppression of stop codons and preventing unintended interactions with the host’s cellular machinery. This forms a stringent genetic firewall, effectively restricting viral propagation to specially engineered cells supplied with the ncAA, thereby significantly elevating biosafety.

Experimental evaluations in genetically modified mammalian XH 293 cell lines demonstrate that PTC virus replication strictly depends on the presence of the ncAA and functional orthogonal machinery. In the absence of either component or in standard mammalian cells, the virus is unable to replicate, thereby establishing a robust multi-layered biosafety mechanism that surpasses conventional attenuation strategies. This precise replication control holds immense promise for vaccine safety in clinical applications, mitigating risks of reversion to virulence or uncontrolled spread.

Animal model studies further corroborate the potential of PTC influenza viruses as immunization agents. In murine, ferret, and guinea pig models, immunization with these engineered viruses induces notably stronger mucosal and systemic immune responses compared to commercial inactivated influenza vaccines. Remarkably, vaccinated mice exhibit full protection against subsequent challenges with wild-type influenza virus, while unvaccinated controls succumb to infection. These findings underscore the enhanced immunogenicity and protective efficacy conferred by the PTC platform, highlighting its relevance for advancing influenza vaccine technology.

Beyond classical infectious disease prevention, the PTC influenza platform exhibits remarkable versatility as a viral vector for cancer immunotherapy. A pioneering application termed the chimeric antigen peptide (CAP) Flu system integrates multiple innovative components: tumor-associated antigen peptides conjugated to viral hemagglutinin via precise bioorthogonal “click” chemistry reaction; immunostimulatory CpG-rich TLR9 agonists tailored to activate dendritic cells; and a gene encoding an anti-PD-L1 nanobody embedded within the viral genome to modulate tumor immune evasion. This sophisticated design enables the virus to elicit a potent, multifaceted immune assault against malignancies after intranasal administration.

In vivo, the CAP Flu system demonstrates profound therapeutic efficacy in a lung metastasis tumor model. Treatment enhances dendritic cell recruitment and activation within the tumor microenvironment and draining lymph nodes, amplifying antigen presentation and priming of both humoral and cellular arms of the immune system. The resultant immune response not only curtails tumor growth but achieves effective suppression of metastatic progression, representing a promising advance in oncolytic viral-based cancer vaccine strategies.

When benchmarked against traditional viral vectors such as adenoviruses and vesicular stomatitis virus (VSV), the PTC influenza vector offers unique advantages. Its hallmark orthogonal genetic attenuation confers exceptional replication control and genetic stability. Moreover, influenza’s intrinsic ability to stimulate robust mucosal immunity—a critical first line of defense rarely elicited by other vectors—adds to its therapeutic appeal. Additionally, the stoichiometric display of antigens physically linked to viral proteins mitigates issues of antigen instability and ensures consistent immune targeting, surpassing limitations encountered with codon-deoptimized or temperature-sensitive strains.

Despite compelling preclinical outcomes, the path to clinical translation involves noteworthy challenges. Preexisting immunity to influenza in the human population could impede vector dissemination and immunogenicity, necessitating strategies to circumvent humoral and cellular immune neutralization. Comprehensive biosafety evaluations addressing the use of non-canonical amino acids are imperative to establish regulatory compliance and public acceptance. Furthermore, specificity for targeting non-pulmonary tumors requires optimization, including tailored antigen payloads and tumor tropism modifications to broaden therapeutic applicability.

The modular plug-and-play architecture of the PTC influenza platform empowers rapid customization of antigen combinations, integration of immunomodulatory elements, and orthogonal control of replication dynamics, positioning it at the vanguard of synthetic biology-enabled vaccine design. As the field advances, this platform holds transformative potential to redefine paradigms in prophylactic vaccination and viral immunotherapy, bridging infectious disease control and oncology within a single versatile genetic chassis.

In summary, the development of site-specifically attenuated influenza viruses through non-canonical amino acid incorporation and orthogonal translation systems marks a significant milestone in synthetic viral vector engineering. By combining unparalleled biosafety, potent mucosal immunogenicity, and adaptable payload capabilities, this technology stands to revolutionize how we confront infectious agents and malignancies alike. Continued research and clinical validation will determine its ultimate impact, but current evidence heralds a new era where engineered influenza viruses transcend their pathogenic origins to become therapeutic powerhouses in modern medicine.

Subject of Research: Engineering of Influenza Viruses as Platforms for Vaccines and Viral Immunotherapies Targeting Infectious Diseases and Cancer

Article Title: From Flu to Therapy: Development of Influenza Viruses as Platforms for Combating Infections and Cancer

News Publication Date: 17-Feb-2026

Web References:

• https://doi.org/10.1016/j.eng.2025.12.007
• https://www.sciencedirect.com/journal/engineering

References: Provided in the original article via DOI link

Keywords: Influenza virus, viral vectors, non-canonical amino acids, premature termination codons, orthogonal translation system, vaccine development, cancer immunotherapy, mucosal immunity, reverse genetics, synthetic biology, chimeric antigen peptide, oncolytic viruses

The influenza virus remains a formidable public health challenge due to its rapid antigenic drift and occasional antigenic shift, mechanisms that allow it to evade immune recognition and reduce vaccine effectiveness. Traditionally, flu vaccines have primarily targeted hemagglutinin, the main protein responsible for viral attachment and entry into host cells. However, the new mRNA vaccine uniquely incorporates coding sequences for neuraminidase as well, an enzyme that facilitates viral release and propagation. This dual-targeting strategy is designed to elicit a broader and more robust immune response, potentially overcoming the limitations of current vaccines that often show variable effectiveness from year to year.

The researchers engineered a lipid nanoparticle (LNP)-encapsulated mRNA vaccine encoding full-length HA and NA proteins derived from the predominant influenza strains predicted for the upcoming season. By leveraging the mRNA vaccine platform, which gained widespread recognition during the COVID-19 pandemic, this approach enables rapid and precise antigen production within host cells, eliciting both humoral and cellular immunity. The inclusion of neuraminidase is particularly notable, as antibodies against NA can inhibit viral spread and are correlated with reduced disease severity, yet have been historically underrepresented in vaccine formulations.

Preclinical studies demonstrated that the vaccine prompts robust antigen expression in vivo, leading to a potent neutralizing antibody response against multiple influenza subtypes. The dual antigen design also showed promise in eliciting cross-reactive immunity, an essential feature given the high mutation rate of influenza viruses. Importantly, the safety profile was thoroughly assessed in animal models, with no significant adverse effects observed, providing compelling evidence for the potential of this vaccine to progress through clinical trials.

A critical aspect of this research is the detailed evaluation of immunogenicity—the vaccine’s ability to stimulate an immune response. Hemagglutination inhibition (HAI) assays revealed significantly higher titers of neutralizing antibodies compared to monovalent HA-only vaccines. Additionally, neuraminidase inhibition (NAI) assays confirmed that the immune system effectively recognized NA, a milestone that has been challenging to achieve in the context of influenza vaccination. The synergy between HA and NA antigens may contribute to a more durable immunity, reducing the frequency and severity of infections during flu season.

The safety analysis encompassed both local and systemic reactions, typical of vaccine studies, recorded in preclinical models. Researchers reported minimal injection site reactions and no systemic toxicity, underscoring the biocompatibility of the LNP-mRNA platform when used for influenza vaccination. These findings not only bolster confidence in the vaccine’s safety but also highlight the potential for this technology to be adapted rapidly to emerging influenza strains or other respiratory pathogens.

From a molecular standpoint, the mRNA constructs were optimized for enhanced stability and translational efficiency. Codon usage was meticulously designed to match human cellular machinery, while untranslated regions (UTRs) were engineered to improve mRNA half-life without triggering excessive innate immune activation, which can interfere with antigen expression. This balance is critical to achieving high protein yield and robust immune priming, a hallmark of successful mRNA vaccines.

Moreover, the vaccine’s ability to induce T-cell responses was thoroughly investigated. CD8+ cytotoxic T lymphocytes (CTLs) play an important role in clearing influenza-infected cells and providing long-term immunity. Flow cytometry and ELISpot assays revealed that vaccinated subjects mounted significant T-cell responses directed against both HA and NA epitopes. This cellular immunity complements the antibody-mediated protection, offering a multi-layered defense against viral infection and possibly contributing to reduced viral replication and transmission.

Another highlight of the study involves the assessment of mucosal immunity, an often-overlooked yet critical component of influenza protection. Secretory IgA antibodies at mucosal surfaces can neutralize viruses at entry points, preventing infection establishment. Preliminary data indicate that the mRNA vaccine may stimulate mucosal immune responses when administered intramuscularly, a finding that warrants further exploration and could have profound implications for vaccine delivery strategies.

One of the paramount challenges in influenza vaccine development is antigenic mismatch; the virus’s high mutation rate often leads to strain variants that escape immunity induced by prior vaccination. The inclusion of neuraminidase antigens might mitigate this issue by presenting conserved regions of the viral NA protein that are less prone to mutation. This potentially broadens the vaccine’s effectiveness against diverse influenza strains and may reduce the necessity for annual reformulation.

The study also addresses manufacturing and scalability considerations inherent in mRNA vaccine technologies. The modular nature of mRNA design allows for rapid adaptation to circulating influenza strains, significantly shortening production timelines compared to traditional egg-based or recombinant protein vaccines. Moreover, the established cold chain logistics and mass production infrastructure developed during the COVID-19 vaccine rollout provide a framework for efficient global distribution of influenza mRNA vaccines.

Looking to the future, experts anticipate that this dual-antigen mRNA vaccine could revolutionize the annual influenza vaccination paradigm, potentially improving global vaccine coverage and efficacy rates. By providing enhanced immunity and a favorable safety profile, this approach aligns with the broader goal of preventing seasonal influenza epidemics and minimizing the burden on healthcare systems worldwide. Ongoing clinical trials are expected to validate these promising preclinical results and bring this transformative vaccine closer to licensure.

The integration of neuraminidase into seasonal influenza vaccines could also influence vaccine policy and public health strategies. Surveillance systems may need to incorporate NA antigenic data to inform vaccine strain selection more comprehensively. Additionally, the enhanced vaccine efficacy might reduce influenza-related hospitalizations and mortalities, contributing to improved population health outcomes, particularly among vulnerable groups such as the elderly and immunocompromised.

This advancement also opens avenues for mRNA vaccine applications beyond influenza. By demonstrating the successful co-expression of multiple antigens and eliciting broad immune responses, the platform can be adapted to complex pathogens requiring multivalent protection. The scientific community anticipates a surge in research leveraging mRNA technology to combat emerging infectious diseases, leveraging lessons learned from this pioneering influenza vaccine study.

Ultimately, the convergence of molecular innovation and immunological insight embodied in this research marks a pivotal step toward more effective, safe, and adaptable vaccines. As global health challenges intensify, such scientific breakthroughs underscore the relentless pursuit required to outpace evolving pathogens and safeguard human health. The study by Rudman Spergel, Lee, Koslovsky, and colleagues ushers in a new era of influenza vaccination that could transform the landscape of infectious disease prevention.

Subject of Research: Immunogenicity and safety evaluation of mRNA-based seasonal influenza vaccines encoding both hemagglutinin and neuraminidase proteins.

Article Title: Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.

Article References:
Rudman Spergel, A.K., Lee, I.T., Koslovsky, K. et al. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase. Nat Commun 16, 5933 (2025). https://doi.org/10.1038/s41467-025-60938-4

Image Credits: AI Generated